I'll take a quick shot at this.
The endpoint in our mCRC
I'll take a quick shot at this.
The endpoint in our mCRC trial is Overall Response Rate (ORR). So that is a useful comparator. The Standard of Care is 6.1%. The ORR for IBI363 in mCRC is 13.6%, according to the Fierce Biotech article. So they can say--with a straight face--that they more than double the ORR of the SOC.
But check out the numbers. There were 22 patients in the trial. 13.6% of 22 is roughly 3 patients with at least a partial response. Another way to look at that is it took 22 patients to achieve 3 responses. In Cytodyn's basket trial it took 5 mCRC patients to get 3 responses. That's a 60% ORR. So, with a very very small sample size, leronlimab looks much better than IBI363. But we won't really know until we get results from our trial, and see if the 60% number holds.
Something else I noticed from the article. Apparently IBI363 works better on the primary tumor. The Overall Survival numbers for the drug in patients with liver metastases was 14 months, while those without metastases lived 17 months. One of leronlimab's strength is controlling metastasis. So I would say we will look pretty good in comparison on that metric.
Those are all monotherapy numbers. The IBI363 numbers are better when paired with bevacizumab--the ORR goes to 15%, and increases to 31% in patients without metastases. Respectable... but our trial is in metastatic patients.
I don't have the OS numbers for leronlimab in mCRC... maybe my69 has them memorized. But once again, its a really small sample size. I don't have the ORR number for the TNBC trial, either; that would be another interesting comparison to make.
None of these mCRC numbers involve an ICI paired with IBI363 or leronlimab. Paired with an ICI the numbers for leronlimab should be quite substantial... based on the MOA and the numbers in the TNBC trial.
In the meantime... we wait on the trial. But I like our chances of becoming
"the backbone immuno-oncology treatment" that IBI363 aspires to be. At least in CCR5-positive cancers.
28
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...
Continue Reading
Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...
Continue Reading
Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...
Continue Reading
A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...
Continue Reading
Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...
Continue Reading
The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...
Continue Reading
A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....
Continue Reading
Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...
Continue Reading
A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...
Continue Reading
A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...
Continue Reading
Top 5 Most Recently Viewed Articles
US LBM Welcomes Milton Truss to Its Family US LBM, a leading distributor of specialty building materials, has made a significant move by acquiring Milton Truss, a well-respected manufacturer specializing in structural building components. This acquisition expands US LBM’s operational capabilities and strengthens its presence in the Southeast, particularly within the...
Continue Reading
The Future of the US Residential Construction Market The residential construction market in the United States is poised to experience significant growth, with estimates suggesting an increase of USD 242.9 million from 2025 to 2029. As household formation rates rise, there is an unmistakable trend towards building more residential units, coupled with an increasing emphasis...
Continue Reading
Unpacking Orbital's New Alliance with Banking Circle Today's chat's all about payments—specifically how Orbital's rolling out the red carpet with Banking Circle to ramp up their multi-currency payment interface. The company's stretching its limbs into the Nordics, Central Europe, Switzerland, and Australia. With a suit like this, Orbital's not just dropping coins into...
Continue Reading
Jorge Blanco Celebrated as a 2025 CRE Tech Influencer Altus Group Limited (TSX: AIF), a leading force in asset and fund intelligence for the commercial real estate sector, is excited to announce that its Chief Commercial Officer, Jorge Blanco, has received recognition as a 2025 CRE Technology Influencer. This accolade comes from a renowned publication dedicated to...
Continue Reading
Investigating Securities Concerns at Unicycive Therapeutics In the fast-paced world of pharmaceuticals, investor sentiment can shift dramatically based on the health of the company and news that emerges. Currently, Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is facing scrutiny as Pomerantz LLP has initiated an investigation concerning potential claims on behalf of its...
Continue Reading